RRx-001, a first-in-class small molecule inhibitor of MYC and a downregulator of CD47, is an "erythrophagoimmunotherapeutic".

Authors :: Oronsky B
Carter CA
Caroen S
Scribner C
Oronsky A
Reid TR
Source :: Oncoimmunology [Oncoimmunology] 2020 Apr 03; Vol. 9 (1), pp. 1746172. Date of Electronic Publication: 2020 Apr 03.
Publication Year :: 2020
Abstract: The main mechanism of action of RRx-001, a pharmaceutically unprecedented sui generis Phase 3 small molecule that is derived from the aerospace industry, is clarified. RRx-001 has demonstrated anticancer activity through antiangiogenic, immune, epigenetic, antioxidant, apoptotic and nitric oxide (NO) pathways, resulting in its pleiomorphic description as an antiangiogenic/vascular normalizer.<br /> (© 2020 The Author(s). Published with license by Taylor & Francis Group, LLC.)

Full Text Access

Tools